Biopharma

New clinical trial map launched in the EU

New clinical trial map launched in the EU

Mar 3, 2025 0

A new clinical trial map is now accessible from the public website of the Clinic...

Takeda's $300M bet on Protagonist's blood cancer drug pays off with phase 3 win

Takeda's $300M bet on Protagonist's blood cancer drug p...

Mar 3, 2025 0

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year a...

Human medicines European public assessment report (EPAR): MenQuadfi, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 18/11/2020, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): MenQuadfi, meningococc...

Novo bets up to $354M per target on Gensaic’s tissue-selective delivery tech

Novo bets up to $354M per target on Gensaic’s tissue-se...

Mar 3, 2025 0

Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million ...

Human medicines European public assessment report (EPAR): Spherox, spheroids of human autologous matrix-associated chondrocytes, Date of authorisation: 10/07/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Spherox, spheroids of ...

Human medicines European public assessment report (EPAR): Efient, prasugrel, Date of authorisation: 24/02/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Efient, prasugrel, Dat...

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib,...

Human medicines European public assessment report (EPAR): Humira, adalimumab, Date of authorisation: 08/09/2003, Revision: 92, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Humira, adalimumab, Da...

Human medicines European public assessment report (EPAR): Ruconest, conestat alfa, Date of authorisation: 28/10/2010, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Ruconest, conestat alf...

Human medicines European public assessment report (EPAR): Atazanavir Viatris (previously Atazanavir Mylan), atazanavir, Date of authorisation: 22/08/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Atazanavir Viatris (pr...

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab,...

An update on the ‘mystery illness’ in DRC

An update on the ‘mystery illness’ in DRC

Mar 3, 2025 0

And other health news stories from the weekend.

STAT+: AbbVie steps into the obesity drug race, licensing medicine from Danish firm

STAT+: AbbVie steps into the obesity drug race, licensi...

Mar 3, 2025 0

The obesity medicine field has gained a new entrant, with AbbVie licensing an ex...

Lilly promotes 'healthy skepticism' toward compounded drugs in new Oscars ad campaign

Lilly promotes 'healthy skepticism' toward compounded d...

Mar 3, 2025 0

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak ...

AbbVie pays Gubra $350M to make late play for obesity space

AbbVie pays Gubra $350M to make late play for obesity s...

Mar 3, 2025 0

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $...

Human medicines European public assessment report (EPAR): Modigraf, tacrolimus, Date of authorisation: 15/05/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Modigraf, tacrolimus, ...

Clinical Trials Information System (CTIS) Bitesize Talk: Revised transparency rules and the new CTIS public portal, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 June 2024, 15:30 (CEST) to 20 June 2024, 17:00 (CEST)

Clinical Trials Information System (CTIS) Bitesize Talk...

Mar 3, 2025 0

Clinical Trials Information System (CTIS) Bitesize Talk: Revised transparency ru...

Clinical Trials Information System (CTIS) bitesize talk: End of transition period and notifications including serious breach, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 October 2024, 15:30 (CEST) to 16 October 2024, 17:00 (CEST)

Clinical Trials Information System (CTIS) bitesize talk...

Mar 3, 2025 0

Clinical Trials Information System (CTIS) bitesize talk: End of transition perio...

Human medicines European public assessment report (EPAR): Torisel, temsirolimus, Date of authorisation: 19/11/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Torisel, temsirolimus,...

3Rs Working Party (3RsWP) plenary meeting - Public session on the 2025-2027 work plan, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 April 2024, 09:30 (CEST) to 2 April 2024, 10:30 (CEST)

3Rs Working Party (3RsWP) plenary meeting - Public sess...

Mar 3, 2025 0

3Rs Working Party (3RsWP) plenary meeting - Public session on the 2025-2027 work...

Opinion: I’m disabled. I’m terrified about what Medicaid cuts could mean for my life

Opinion: I’m disabled. I’m terrified about what Medicai...

Mar 3, 2025 0

Medicaid cuts could force disabled people out of the public sphere and into nurs...

Meet the research teams facing off in STAT Madness 2025. Voting is now open

Meet the research teams facing off in STAT Madness 2025...

Mar 3, 2025 0

Voting is now open for STAT Madness, our bracket-style competition in which read...

STAT+: How AI can distort clinical decision-making to prioritize profits over patients

STAT+: How AI can distort clinical decision-making to p...

Mar 3, 2025 0

Boston Children's Hospital's Ken Mandl talks about the risk of commercial intere...

Opinion: ‘Post-vaccination syndrome’: a dubious diagnosis that could do harm

Opinion: ‘Post-vaccination syndrome’: a dubious diagnos...

Mar 3, 2025 0

The science behind the “post-vaccination syndrome” study is dubious — but the ha...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.